March 23 (Reuters) - Pfizer Inc:
* PFIZER REPORTS TOP-LINE RESULTS FROM A STUDY OF CHANTIX®/CHAMPIX® (VARENICLINE) IN ADOLESCENT SMOKERS
* PFIZER INC - STUDY DID NOT MEET ITS PRIMARY ENDPOINT
* PFIZER INC - ADVERSE EVENT PROFILE OF CHANTIX/CHAMPIX OBSERVED IN STUDY OF ADOLESCENT SMOKERS WAS SIMILAR TO THAT SEEN IN STUDIES OF ADULTS
* PFIZER - IN TRIAL, MOST COMMON ADVERSE EVENTS THAT OCCURRED IN AT LEAST 5 PERCENT OF PATIENTS WERE NAUSEA, HEADACHE, VOMITING, OTHERS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
